The Orange County District Attorney’s office has suspended its controversial DNA harvesting program, citing budget constraints and ongoing legal challenges over its constitutionality. The move comes as the program—used to collect DNA from arrestees without conviction—faces a $42.5 million lawsuit settlement demand and a 2025 fiscal year shortfall of $18.3 million in discretionary funds. Here’s what it means for public-sector genetics firms, lab supply chains, and the broader forensic market.
The Bottom Line
- Forensic DNA testing revenue in California could contract by 5–8% YoY as public-sector demand drops, pressuring Illumina (NASDAQ: ILMN) and Thermo Fisher (NYSE: TMO)—the top two suppliers—whose lab reagent sales account for 38% and 29% of their respective forensic divisions.
- Private equity-backed genetics startups (e.g., Verogen (NASDAQ: VRGN), valuation: $1.2B) may see accelerated M&A activity as public-sector clients pivot to commercial partnerships, though their burn rates remain elevated at $45M/quarter.
- Inflation-adjusted lab costs for law enforcement could rise 12–15% as private labs fill the gap, though the DOJ’s 2026 budget proposal includes $1.1B for forensic innovation—potentially redirecting funds to private players.
Why the DNA Program’s Suspension Matters to Wall Street
The OC DA’s program was one of the largest public-sector DNA collection initiatives in the U.S., processing over 12,000 samples annually. Its suspension disrupts a $3.8 billion forensic DNA market that grew 9.2% in 2025, per BCC Research. The immediate impact? A 15% drop in Illumina’s forensic reagent orders this quarter, according to internal supply chain data reviewed by Bloomberg.
Here’s the math: The program accounted for ~$3.1M/year in direct lab testing revenue for Illumina and Thermo Fisher, or roughly 1.2% of Illumina’s forensic segment. But the ripple effect extends to private equity-backed firms like Verogen, which relies on public-sector contracts for 40% of its $180M annual revenue. Analysts at Jefferies project a 20% uptick in Verogen’s M&A activity as it seeks to offset lost public contracts.
“The suspension is a double-edged sword for Illumina. Short-term, they’ll see a revenue hit, but long-term, it accelerates the shift to commercial forensic markets—where Illumina’s margins are 30% higher than in public-sector testing.”
— David King, Senior Biotech Analyst, Evercore ISI
How Competitors Are Positioning for the Fallout
While Illumina and Thermo Fisher brace for near-term revenue pressure, BGI Group (HKEX: 2499), the Chinese genomics giant, stands to gain. BGI’s forensic division—expanding aggressively in the U.S. via partnerships with state labs—has already secured a $50M contract with the Texas Department of Public Safety to replace suspended DNA programs. “BGI’s entry into the U.S. forensic market is no accident,” notes The Wall Street Journal, citing internal BGI documents.
Meanwhile, private lab operators like Eurofins Scientific (OTC: EFNYY) are ramping up marketing to law enforcement agencies. Eurofins’ forensic division reported a 14% YoY revenue increase in Q1 2026, driven by public-sector contract wins in Florida and Arizona. The firm’s CEO, Wolfgang Baumann, told investors in a May earnings call that the OC DA’s suspension “validates our strategy of diversifying away from single-state dependencies.”
| Company | Forensic Revenue (2025) | Public-Sector Exposure | Q2 2026 Guidance Adjustment |
|---|---|---|---|
| Illumina (ILMN) | $420M | 35% | Downward revision of $12M |
| Thermo Fisher (TMO) | $310M | 28% | Stable (offset by commercial growth) |
| Verogen (VRGN) | $72M | 40% | No guidance change (PE-backed) |
| Eurofins (EFNYY) | $98M | 22% | Upward revision of $8M |
What Happens Next: Legal, Budget, and Market Trajectories
The OC DA’s suspension hinges on two critical factors: the outcome of the lawsuit settlement and the 2026 state budget negotiations. The lawsuit, filed by the ACLU, argues the program violates the Fourth Amendment by collecting DNA without probable cause. A bench trial is scheduled for October 2026, with potential damages exceeding $42.5M—equivalent to 12% of the OC DA’s annual budget.
If the program is permanently halted, Illumina’s forensic segment could see a cumulative $48M revenue hit over three years, per MarketWatch estimates. However, the DOJ’s 2026 budget proposal includes $1.1 billion for “next-generation forensic technologies,” which could redirect funds to private labs. “This isn’t just about OC,” warns Dr. Henry Lee, forensic science consultant and former FBI lab director. “It’s a test case for how far states will go to balance budgets without gutting public safety tools.”
“The suspension is a microcosm of a larger trend: cash-strapped governments outsourcing forensic work to private labs. For companies like Illumina, the question isn’t if they’ll lose public contracts—it’s how fast they can pivot to commercial markets where margins are higher.”
— Sarah Zhang, Biotech Portfolio Manager, Fidelity Investments
The Inflation and Supply Chain Domino Effect
The suspension could also tighten lab reagent supply chains, pushing up costs for law enforcement. Illumina’s forensic reagents are already in short supply due to a 2025 production bottleneck at its California facility, where labor shortages have delayed shipments by 4–6 weeks. With public-sector demand shifting to private labs, Thermo Fisher’s reagent prices may rise 12–15% to offset lost volume, according to Reuters supply chain data.
For small forensic labs—many of which are family-owned or backed by angel investors—the impact is more immediate. A 2025 survey by the American Society of Crime Laboratory Directors found that 68% of labs operate at a loss or break-even margin. The OC DA’s suspension could force another 10–15% of these labs to close or merge, further consolidating the market in favor of larger players like BGI and Eurofins.
The Bottom Line for Investors
Short-term, Illumina (ILMN) and Thermo Fisher (TMO) face revenue headwinds, but the long-term play favors companies with commercial forensic portfolios. Verogen (VRGN) and Eurofins (EFNYY) are best positioned to capitalize on the shift, though their valuations remain sensitive to public-sector contract wins. For public-sector investors, the story is about budget allocation: Will states redirect forensic funds to private labs, or will they cut testing altogether?
The OC DA’s suspension is a canary in the coal mine. If other districts follow suit, the forensic DNA market could see a 10–15% contraction by 2027—unless private labs step in to fill the void. The question for investors isn’t whether the program will return, but whether the market will adapt before the next budget crisis hits.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
